The changing face of graft-versus-host disease.
Despite advances in the procedure and posttransplantation immunosuppressive therapy, more than half of allogeneic hematopoietic stem cell transplant (HSCT) recipients develop graft-versus-host disease (GVHD), which remains a major cause of morbidity and mortality. Modern HSCT protocols have resulted in substantial alterations in the timing and relative incidences of acute and chronic GVHD, making traditional classification schemes obsolete. This article reviews major changes in HSCT during the past decade, evolving concepts of acute and chronic GVHD (including new diagnostic criteria) and the expanding spectrum of cutaneous GVHD. It focuses on observations that have led to a better delineation of the full constellation of skin findings in chronic cutaneous GVHD, including lichen sclerosus, morpheaform lesions, and eosinophilic fasciitis. Recent insights into pathogenesis of GVHD, lessons from GVHD arising in settings outside HSCT, and therapeutic advances also are highlighted.
Schaffer
Julie V
JV
Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY 10016, USA. jvschaffer@gmail.com
D000208:Acute Disease; D002908:Chronic Disease; D006086:Graft vs Host Disease / Q000150:complications* / Q000188:drug therapy / Q000473:pathology*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D016377:Organ Transplantation / Q000009:adverse effects; D012871:Skin Diseases / Q000175:diagnosis / Q000209:etiology*; D019172:Transplantation Conditioning